Zacks Investment Research downgraded shares of Genocea Biosciences, Inc. (NASDAQ:GNCA) from a hold rating to a sell rating in a report released on Friday morning.

According to Zacks, “Genocea Biosciences, Inc. is involved in developing vaccines. The company’s proprietary discovery platform consists of AnTigen Lead Acquisition System which designs vaccines that stimulate T cell immunity. Its product portfolio which are in different clinical trials consist of GEN-003, HSV-2 infections, GEN-004 and HSV-2 prophylaxis and malaria. Genocea Biosciences, Inc. is headquartered in Cambridge, Massachusetts. “

GNCA has been the subject of a number of other reports. ValuEngine upgraded shares of Genocea Biosciences from a sell rating to a hold rating in a research report on Monday, July 24th. Piper Jaffray Companies reissued an overweight rating and issued a $18.00 price objective (up from $17.00) on shares of Genocea Biosciences in a research note on Tuesday, July 25th. Cowen and Company reissued an outperform rating and issued a $40.00 price objective on shares of Genocea Biosciences in a research note on Tuesday, July 25th. Finally, Needham & Company LLC raised shares of Genocea Biosciences from a hold rating to a buy rating and set a $12.00 price objective on the stock in a research note on Monday, July 24th. Two equities research analysts have rated the stock with a sell rating and five have assigned a buy rating to the stock. Genocea Biosciences currently has a consensus rating of Hold and a consensus price target of $16.52.

Shares of Genocea Biosciences (NASDAQ GNCA) opened at 3.97 on Friday. The stock has a 50 day moving average price of $5.16 and a 200 day moving average price of $5.50. The company’s market capitalization is $113.31 million. Genocea Biosciences has a 1-year low of $3.28 and a 1-year high of $7.29.

Genocea Biosciences (NASDAQ:GNCA) last released its quarterly earnings results on Wednesday, August 9th. The biotechnology company reported ($0.54) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.46) by $0.08. Analysts forecast that Genocea Biosciences will post ($1.95) earnings per share for the current year.

ILLEGAL ACTIVITY WARNING: “Genocea Biosciences, Inc. (GNCA) Rating Lowered to Sell at Zacks Investment Research” was first reported by The Cerbat Gem and is the sole property of of The Cerbat Gem. If you are reading this story on another publication, it was illegally stolen and reposted in violation of U.S. and international trademark & copyright law. The correct version of this story can be viewed at https://www.thecerbatgem.com/2017/08/14/genocea-biosciences-inc-gnca-rating-lowered-to-sell-at-zacks-investment-research.html.

In other Genocea Biosciences news, CFO Jonathan Poole sold 45,000 shares of the business’s stock in a transaction on Monday, July 24th. The shares were sold at an average price of $6.00, for a total transaction of $270,000.00. Following the sale, the chief financial officer now owns 84,247 shares of the company’s stock, valued at $505,482. The transaction was disclosed in a legal filing with the SEC, which is accessible through this link. Insiders own 6.70% of the company’s stock.

Several hedge funds have recently modified their holdings of GNCA. Ameriprise Financial Inc. boosted its stake in shares of Genocea Biosciences by 34.1% in the first quarter. Ameriprise Financial Inc. now owns 19,933 shares of the biotechnology company’s stock valued at $121,000 after buying an additional 5,068 shares in the last quarter. Keybank National Association OH acquired a new stake in shares of Genocea Biosciences during the first quarter valued at $147,000. JPMorgan Chase & Co. acquired a new stake in shares of Genocea Biosciences during the first quarter valued at $217,000. FMR LLC boosted its stake in shares of Genocea Biosciences by 0.4% in the first quarter. FMR LLC now owns 4,274,804 shares of the biotechnology company’s stock valued at $26,033,000 after buying an additional 18,574 shares in the last quarter. Finally, Segantii Capital Management Ltd acquired a new stake in shares of Genocea Biosciences during the first quarter valued at $160,000. 55.20% of the stock is currently owned by institutional investors.

About Genocea Biosciences

Genocea Biosciences, Inc, is harnessing the power of T cell immunity to develop vaccines and immunotherapies company. The Company uses its discovery platform, AnTigen Lead Acquisition System (ATLAS), to design vaccines and immunotherapies that act, in part, through T cell (or cellular) immune responses.

Get a free copy of the Zacks research report on Genocea Biosciences (GNCA)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Receive News & Stock Ratings for Genocea Biosciences Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Genocea Biosciences Inc. and related stocks with our FREE daily email newsletter.